Medication Integration in Treatment of Comorbid Adolescent Substance Users/Attention Deficit Hyperactivity Disorder (MIP)
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder
About this trial
This is an interventional treatment trial for Attention Deficit Hyperactivity Disorder focused on measuring Comorbid, ADHD, SUD, ASU
Eligibility Criteria
Inclusion Criteria:
- Age 13-17 years
- Caregiver able to participate in treatment
- One day of alcohol use to intoxication or illegal drug use in the past 30 days (or 30 days prior to living in a controlled environment)
- endorsement of one or more DSM-IV symptoms of Substance Use or Alcohol Dependence/Abuse
- meet ASAM criteria for outpatient substance use treatment
- meet DSM-IV criteria for ADHD (with or without onset prior to age 7)
- not enrolled in any behavioral treatment
Exclusion Criteria:
- MDD
- Bipolar Disorder
- Mental Retardation
- PDD
- medical or psychiatric illness requiring hospitalization
- current psychotic features
- currently suicidal
Sites / Locations
- Roberto Clemente Center
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Family Counseling with MIP Protocol
Historical Control
We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.